[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354186-105":59,"doc-detail-354186-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","management-and-outcomes-of-patients-with-liver-cancer-in-china-and-the-united-states","Management and outcomes of patients with liver cancer in China and the United States","","Management and outcomes of liver cancer in China were insufficiently studied. This multicenter retrospective cohort study evaluated management strategies and prognosis for Chinese patients and compared results with the United States using SEER data. Thirteen hospitals across 10 provinces contributed cases diagnosed from 2016–2017, with survival follow-up through December 2023. Multivariable Cox regression identified prognostic factors, and cross-country comparisons assessed treatment patterns and survival.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/management-and-outcomes-of-patients-with-liver-cancer-in-china-and-the-united-states/354186/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/management-and-outcomes-of-patients-with-liver-cancer-in-china-and-the-united-states/354186.png","ImageObject",300,407,{"name":92,"@type":93},"Cipher","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the primary aim of the study?","Question",{"text":112,"@type":113},"To evaluate management and prognosis of liver cancer patients in China using a comprehensive multicenter analysis, and compare findings with United States data.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were patients and data collected in this retrospective cohort study?",{"text":117,"@type":113},"Patients were drawn from 13 hospitals across 10 provinces in China, including primary liver cancer cases diagnosed between January 2016 and December 2017, with data on sociodemographics, lifestyle factors, stage at diagnosis, and first-line treatment.",{"name":119,"@type":110,"acceptedAnswer":120},"Which factors were identified as key prognostic elements?",{"text":121,"@type":113},"Both the stage at diagnosis and surgical intervention were key prognostic factors in China and the United States, and the study also reported poor overall prognosis.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},354186,1790641130,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},687208528416,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Original Article  \nManagement and outcomes of patients with liver cancer in China and the United States  \nMengyuan Xu1,2, Qiushuo Geng3,4, Tianhao Shan1, Manqi Liu1, Jianguo Chen5, Meicen Liu1, Bingfeng Han1, Changfa Xia6, Xianhui Ran1, Kexin Sun1, Shaoming Wang1, Yubing Shen1, Ru Chen1, Li Li1, Hong Zhao7, Wanqing Chen1, Lingeng Lu8, Yefan Zhang7, Hongmei Zeng1  \n1National Central Cancer Registry & State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100021, China;  \n2School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100021, China;  \n3School of Medical Device, Shenyang Pharmaceutical University, Benxi, Liaoning 117004, China;  \n4School of Biomedical Engineering, Tsinghua University, Beijing 100084, China;  \n5Qidong Cancer Registry, Qidong Liver Cancer Institute/Qidong People’s Hospital/Qidong Hospital of Nantong University, Nantong, Jiangsu 226200, China;  \n6Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China;  \n7Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100021, China;  \n8Department of Chronic Disease Epidemiology, Yale School of Public Health, Yale Cancer Center, Yale University, New Haven, CT 06510, USA.  \nAbstract  \nBackground: The management and outcomes of liver cancer in China have not been well studied. This study aimed to evaluate the management and prognosis of patients with liver cancer in China through a comprehensive multicenter analysis and to compare these findings with data from the United States (US) .  \nMethods: We conducted a retrospective cohort study using data from 13 hospitals across 10 provinces in China, covering patients diagnosed with primary liver cancer between January 2016 and December 2017. We collected data on sociodemographic characteristics, lifestyle factors, stage at diagnosis, and first-line treatment. Patients’ survival outcomes were tracked using active and passive follow-up methods until December 2023. Multivariable Cox regression was used to identify prognostic factors. We further compared treatment patterns and prognoses of liver cancer patients between 13 hospitals in China and the Surveillance, Epidemiology, and End Results (SEER) cohort in the US.  \nResults: A total of 4951 patients with liver cancer from China and 18,365 from the Surveillance, Epidemiology, and End Results cohort were analyzed. In the Chinese cohort, commonly used treatments, ranked from highest to lowest, were surgery (37.3%, 1821/4879), interventional therapy (32.1%, 1570/4898), chemotherapy (17.4%, 850/4877), radiofrequency ablation (6.9%, 337/4872), radiotherapy (3.7%, 182/4890), and targeted therapy (2.6%, 127/4875) . Surgery rates for patients with liver cancer in stages I to IV were 59.2%(309/522), 58.8%(443/753), 39.0%(328/841), and 18.6%(141/760), respectively. According to the stage at diagnosis, 5-year survival rates for patients in stages I to IV were 48.1%(95% confidence interval [CI]: 44.0–52.6%), 37.8%(95% CI: 34.5–41.4%), 24.0%(95% CI: 21.3–27.0%), and 8.0%(95% CI: 6.2–10.1%), respectively. Compared with the US, China had higher surgery rates and stage-specific survival for patients with liver cancer across all stages. Data from both countries indicated a poor prognosis for liver cancer, with the stage at diagnosis and surgical intervention being key prognostic factors in both China and the US.  \nConclusion: The present findings underscore the urgent need for early diagnosis and curative treatment interventions such as surgery to enhance survival outcomes for patients with ","cbCaimTGfnsyTjUb","https://ap.wps.com/l/cbCaimTGfnsyTjUb","pdf",3271886,"English","# Abstract\n# Introduction\n## Background\n## Purpose\n# Methods\n## Study design and data sources\n## Variables and follow-up\n# Results\n## Treatment patterns\n## Survival outcomes\n## Cross-country comparison\n# Conclusion","[{\"question\":\"What was the primary aim of the study?\",\"answer\":\"To evaluate management and prognosis of liver cancer patients in China using a comprehensive multicenter analysis, and compare findings with United States data.\"},{\"question\":\"How were patients and data collected in this retrospective cohort study?\",\"answer\":\"Patients were drawn from 13 hospitals across 10 provinces in China, including primary liver cancer cases diagnosed between January 2016 and December 2017, with data on sociodemographics, lifestyle factors, stage at diagnosis, and first-line treatment.\"},{\"question\":\"Which factors were identified as key prognostic elements?\",\"answer\":\"Both the stage at diagnosis and surgical intervention were key prognostic factors in China and the United States, and the study also reported poor overall prognosis.\"}]","Management and outcomes of patients with liver cancer in China and the United States | PDF",1790109386,25,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bb83cbab9318d07496f75c8f6b8da396.webp",983,1324,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/25043b813db433532acc2f438fed5d23.webp",982,1323,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/48073ea97018481b69484908d8215178.webp",981,1321,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2cfbbeb019898dc5135ca0fe8ac96c93.webp",980,1320]